$35.25
2.97% today
Nasdaq, May 16, 08:48 pm CET
ISIN
US4131971040
Symbol
HRMY

Harmony Biosciences Holdings Stock price

$34.23
+5.48 19.06% 1M
+1.02 3.06% 6M
-0.18 0.52% YTD
+4.53 15.25% 1Y
-4.61 11.87% 3Y
-2.78 7.51% 5Y
-2.78 7.51% 10Y
Nasdaq, Closing price Thu, May 15 2025
+0.84 2.52%
ISIN
US4131971040
Symbol
HRMY
Sector
Industry

Key metrics

Market capitalization $1.97b
Enterprise Value $1.67b
P/E (TTM) P/E ratio 13.05
EV/FCF (TTM) EV/FCF 7.52
EV/Sales (TTM) EV/Sales 2.24
P/S ratio (TTM) P/S ratio 2.64
P/B ratio (TTM) P/B ratio 2.73
Revenue growth (TTM) Revenue growth 20.62%
Revenue (TTM) Revenue $744.85m
EBIT (operating result TTM) EBIT $195.04m
Free Cash Flow (TTM) Free Cash Flow $221.39m
Cash position $506.95m
EPS (TTM) EPS $2.62
P/E forward 11.16
P/S forward 2.34
EV/Sales forward 1.98
Short interest 12.43%
Show more

Is Harmony Biosciences Holdings a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,785 stocks worldwide.

Harmony Biosciences Holdings Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Harmony Biosciences Holdings forecast:

8x Buy
89%
1x Sell
11%

Analyst Opinions

9 Analysts have issued a Harmony Biosciences Holdings forecast:

Buy
89%
Sell
11%

Financial data from Harmony Biosciences Holdings

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
745 745
21% 21%
100%
- Direct Costs 185 185
22% 22%
25%
560 560
20% 20%
75%
- Selling and Administrative Expenses 183 183
20% 20%
25%
- Research and Development Expense 158 158
86% 86%
21%
219 219
4% 4%
29%
- Depreciation and Amortization 24 24
2% 2%
3%
EBIT (Operating Income) EBIT 195 195
4% 4%
26%
Net Profit 153 153
11% 11%
21%

In millions USD.

Don't miss a Thing! We will send you all news about Harmony Biosciences Holdings directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Harmony Biosciences Holdings Stock News

Neutral
Seeking Alpha
10 days ago
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY ) Q1 2025 Earnings Call May 6, 2025 8:30 AM ET Company Participants Brennan Doyle - Head, Investor Relations Jeffrey Dayno - President and Chief Executive Officer Adam Zaeske - Chief Commercial Officer Kumar Budur - Chief Medical and Scientific Officer Sandip Kapadia - Chief Financial Officer Conference Call Participants Graig Suvannavejh - Mizuho...
Neutral
Business Wire
10 days ago
​PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced strong year-over-year revenue growth for WAKIX® of 20% in the first quarter 2025, on its way to a potential $1B+ opportunity in narcolepsy alone and poised for additional growth from its next-gen pitolisant development programs. The company has demonstrated four consecutive years of profit...
Neutral
Business Wire
17 days ago
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on May 6, 2025, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 800-267-6316 (dome...
More Harmony Biosciences Holdings News

Company Profile

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders. Its product WAKIX is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded on July 25, 2017 and is headquartered in Plymouth Meeting, PA.

Head office United States
CEO Jeffrey Dayno
Employees 268
Founded 2017
Website www.harmonybiosciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today